Jurij Petrin

SVP, Head of New Market Development at BeOne Medicines

Jurij Petrin joined BeiGene in 2021 and currently serves as Head of New Market Development. Before joining BeiGene, he served more than three years as Senior Vice President of Global Regulatory Affairs at the contract research organization PRA Health Sciences. He previously founded two companies, Pharmaceutical Regulatory Services, a regulatory consultancy; and PRS Clinical, a CRO. While running PRS and PRS Clinical, he established a network of regulatory and clinical/medical consultants and CROs in more than 90 countries, providing strategic regulatory, clinical, and product registration support to many products in various stages of development worldwide.

Earlier in his career, Dr. Petrin spent more than nine years at Bristol Myers Squibb as Medical Director for Central and Eastern Europe, Executive Director of International Regulatory Affairs, and Vice President of Intercontinental Regulatory Science. He has also served as a consultant to PhRMA on regulatory and market-introduction policy issues for Asia Pacific, with a focus on regulatory agencies in China, Japan, South Korea, Singapore, and Malaysia.

He received his M.D. from the University of Ljubljana, Slovenia, and completed a research fellowship at the University of Michigan.

Location

Princeton, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


BeOne Medicines

36 followers

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.


Industries

Employees

5,001-10,000

Links